BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 26940510)

  • 1. Emerging drugs for the treatment of hepatitis B.
    Fung J; Lai CL; Seto WK; Yuen MF
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):183-93. PubMed ID: 26940510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antivirals for the treatment of chronic hepatitis B.
    Soriano V; Barreiro P; Benitez L; Peña JM; de Mendoza C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):843-851. PubMed ID: 28521532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B core protein as a therapeutic target.
    Mak LY; Wong DK; Seto WK; Lai CL; Yuen MF
    Expert Opin Ther Targets; 2017 Dec; 21(12):1153-1159. PubMed ID: 29065733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status and future directions of hepatitis B antiviral drug discovery.
    Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
    Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targets for hepatitis B virus therapy.
    Testoni B; Durantel D; Zoulim F
    Liver Int; 2017 Jan; 37 Suppl 1():33-39. PubMed ID: 28052622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B.
    Yuan HJ; Lee WM
    Curr Mol Med; 2007 Mar; 7(2):185-97. PubMed ID: 17346170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in antivirals against hepatitis B virus.
    Wang YJ; Yang L; Zuo JP
    Virus Res; 2016 Feb; 213():205-213. PubMed ID: 26732483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.
    Qiu LP; Chen L; Chen KP
    Fundam Clin Pharmacol; 2014 Aug; 28(4):364-81. PubMed ID: 24118072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
    Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
    J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future anti-HBV strategies.
    Gane EJ
    Liver Int; 2017 Jan; 37 Suppl 1():40-44. PubMed ID: 28052637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus.
    Cheng X; Guan W; Sun S; Li B; Li H; Kang F; Kang J; Yang D; Nassal M; Sun D
    PLoS One; 2015; 10(12):e0145746. PubMed ID: 26699621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.